person · Reporting owner

Simonian Nancy A

Disclosed activity across 4 companies

Tapewire entity: 63890
SEC CIK: 0001359574

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Evelo Biosciences, Inc.EVLO · Entity 108468	Director	June 17, 2020	June 18, 2020
Generate Biomedicines, Inc.GENB · Entity 1553	Director	February 26, 2026	March 02, 2026
Syros Pharmaceuticals, Inc.SYRS · Entity 85437	Director	December 02, 2024	December 04, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Evelo Biosciences, Inc.

Report date June 17, 2020 · Filed June 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2030-06-17	Direct	15,690	Reported balance After 2020-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-17 · Grant · Acquired 15,690 · Balance 15,690 F1: The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date.

Generate Biomedicines, Inc.

Report date February 26, 2026 · Filed March 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25	Direct	29,561	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Syros Pharmaceuticals, Inc.

Report date December 02, 2024 · Filed December 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,000	Reported balance After 2024-12-02 transaction · row 1 1 source row Row 1 · 2024-12-02 · Sale · Disposed 37,070 · Balance 4,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 62,753 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.25 · Expires 2024-05-16	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2025-05-15	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.82 · Expires 2026-05-20	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.60 · Expires 2027-05-19	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.77 · Expires 2028-05-18	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.38 · Expires 2029-05-20	Direct	Reported balance After 2023-12-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-12-14 · Disposition to issuer · Disposed 7,038 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15	Direct	Reported balance After 2023-12-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-12-14 · Disposition to issuer · Disposed 3,171 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14	Direct	Reported balance After 2023-12-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13	Direct	Reported balance After 2023-12-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2026 Filed Mar 2, 2026 17:55 UTC	Generate Biomedicines, Inc. GENB · Entity 1553	GrantStock Option (Right to Buy) · Derivative	29,561	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001193125-26-085903 · ownership.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document
December 02, 2024 Filed Dec 4, 2024 17:00 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	SaleCommon Stock	37,070	$0.27	$10,016.31	Disclosure SEC source: 0000950170-24-133338 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
November 25, 2024 Filed Nov 27, 2024 17:00 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	SaleCommon Stock	134,713	$0.27	$35,739.36	Disclosure SEC source: 0000950170-24-131591 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,070 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2604 to $0.2723, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
October 31, 2024 Filed Nov 4, 2024 17:01 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionRestricted Stock Units · Derivative	40,125	$0.00	$0.00	Disclosure SEC source: 0000950170-24-120874 · ownership.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document
October 31, 2024 Filed Nov 4, 2024 17:01 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionCommon Stock	40,125	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-120874 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
June 05, 2024 Filed Jun 7, 2024 16:30 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $5.30	$0.00	Disclosure SEC source: 0000950170-24-070706 · ownership.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document
June 05, 2024 Filed Jun 7, 2024 16:30 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0000950170-24-070706 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,658 Read SEC document
April 01, 2024 Filed Apr 2, 2024 16:59 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Tax withholdingCommon Stock	14,052	$5.12	$71,946.24	Disclosure SEC source: 0000950170-24-040308 · ownership.xml · nonDerivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,658 F2 · kind: Represents shares used to cover tax withholding upon the release of restricted stock units. Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:59 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionRestricted Stock Units · Derivative	39,566	$0.00	$0.00	Disclosure SEC source: 0000950170-24-040308 · ownership.xml · derivative · entry 5 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,134 Underlying: Common Stock · 39,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024. Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:59 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionRestricted Stock Units · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0000950170-24-040308 · ownership.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:59 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionCommon Stock	39,566	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-040308 · ownership.xml · nonDerivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:59 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionCommon Stock	6,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-040308 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerRestricted Stock Units · Derivative	2,044	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 11 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,044 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	3,676	Not disclosed Strike: $135.63	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 10 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,676 shares Expires 2032-05-13 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	3,462	Not disclosed Strike: $147.50	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 9 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,462 shares Expires 2031-05-14 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	3,171	Not disclosed Strike: $160.33	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 8 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,171 shares Expires 2030-05-15 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	7,038	Not disclosed Strike: $64.38	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 7 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 7,038 shares Expires 2029-05-20 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	9,260	Not disclosed Strike: $56.77	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 6 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,260 shares Expires 2028-05-18 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	9,260	Not disclosed Strike: $66.60	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 5 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,260 shares Expires 2027-05-19 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	9,260	Not disclosed Strike: $38.82	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,260 shares Expires 2026-05-20 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	9,260	Not disclosed Strike: $39.94	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,260 shares Expires 2025-05-15 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerStock Options (Right to Buy) · Derivative	8,750	Not disclosed Strike: $34.25	Not disclosed	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,750 shares Expires 2024-05-16 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. Read SEC document
December 14, 2023 Filed Dec 15, 2023 18:46 UTC	Seagen Inc. SGEN · Entity 13956	Disposition to issuerCommon Stock	62,753	$229.00	$14,370,437.00	Disclosure SEC source: 0000950170-23-070884 · ownership.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · shares: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · price: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:23 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Disposition to issuerStock Option (right to buy) · Derivative	30,399	Not disclosed Strike: $114.10	Not disclosed	Disclosure SEC source: 0000950170-23-068283 · ownership.xml · derivative · entry 5 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,399 shares Expires 2031-02-16 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. F4 · derivative.exercise_date: This option vested as to 25% of the shares on February 28, 2022, with the remainder vesting in equal monthly installments thereafter through February 28, 2025. Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:23 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Disposition to issuerStock Option (right to buy) · Derivative	29,399	Not disclosed Strike: $75.40	Not disclosed	Disclosure SEC source: 0000950170-23-068283 · ownership.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,399 shares Expires 2030-02-12 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. F3 · derivative.exercise_date: This option vested as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments thereafter through February 28, 2024. Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:23 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Disposition to issuerStock Option (right to buy) · Derivative	28,001	Not disclosed Strike: $100.90	Not disclosed	Disclosure SEC source: 0000950170-23-068283 · ownership.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,001 shares Expires 2028-02-15 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. F1 · derivative.exercise_date: Fully vested. Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:23 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Disposition to issuerStock Option (right to buy) · Derivative	17,499	Not disclosed Strike: $109.00	Not disclosed	Disclosure SEC source: 0000950170-23-068283 · ownership.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,499 shares Expires 2027-02-09 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. F1 · derivative.exercise_date: Fully vested. Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:23 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Disposition to issuerStock Option (right to buy) · Derivative	7,500	Not disclosed Strike: $121.70	Not disclosed	Disclosure SEC source: 0000950170-23-068283 · ownership.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2026-09-15 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. F1 · derivative.exercise_date: Fully vested. Read SEC document
November 01, 2023 Filed Nov 2, 2023 16:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Tax withholdingCommon Stock	13,401	$2.22	$29,750.22	Disclosure SEC source: 0001209191-23-054174 · doc4.xml · nonDerivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,144 F2 · kind: Represents shares used to cover tax withholding on a restricted stock unit release. Read SEC document
October 31, 2023 Filed Nov 2, 2023 16:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionRestricted Stock Units · Derivative	40,125	$0.00	$0.00	Disclosure SEC source: 0001209191-23-054174 · doc4.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,125 Underlying: Common Stock · 40,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024. Read SEC document
October 31, 2023 Filed Nov 2, 2023 16:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionCommon Stock	40,125	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-054174 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
May 31, 2023 Filed Jun 2, 2023 18:20 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	2,044	$0.00	$0.00	Disclosure SEC source: 0001203311-23-000059 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,797 F1 · security: These securities are restricted stock units and will be settled in common stock upon vesting. F2 · shares: These restricted stock units shall vest in full on May 31, 2024. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 03, 2023 Filed Apr 4, 2023 18:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Tax withholdingCommon Stock	1,852	$2.58	$4,778.16	Disclosure SEC source: 0001209191-23-022969 · doc4.xml · nonDerivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,420 F3 · kind: Represents shares used to cover tax withholding on a restricted stock unit release. Read SEC document
March 31, 2023 Filed Apr 4, 2023 18:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionRestricted Stock Units · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-022969 · doc4.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document
March 31, 2023 Filed Apr 4, 2023 18:54 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Exercise / conversionCommon Stock	6,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-022969 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document
February 16, 2023 Filed Feb 21, 2023 16:17 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantRestricted Stock Units · Derivative	118,700	$0.00	$0.00	Disclosure SEC source: 0001209191-23-011151 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,700 Underlying: Common Stock · 118,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter. F2 · derivative.expiration_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter. Read SEC document
December 12, 2022 Filed Dec 14, 2022 17:49 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	8,750	$0.00 Strike: $36.70	$0.00	Disclosure SEC source: 0001203311-22-000065 · edgardoc.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2023-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options were fully vested on 5/16/14. Read SEC document
December 12, 2022 Filed Dec 14, 2022 17:49 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	8,750	$36.70	$321,125.00	Disclosure SEC source: 0001203311-22-000065 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:36 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantRestricted Stock Units · Derivative	80,250	$0.00	$0.00	Disclosure SEC source: 0001209191-22-053315 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,250 Underlying: Common Stock · 80,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. F3 · derivative.expiration_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:36 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantStock Option (right to buy) · Derivative	115,000	$0.00 Strike: $6.73	$0.00	Disclosure SEC source: 0001209191-22-053315 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-10-05 F1 · derivative.exercise_date: This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024. Read SEC document
May 13, 2022 Filed May 17, 2022 19:28 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,676	$0.00 Strike: $135.63	$0.00	Disclosure SEC source: 0000899243-22-018458 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 Underlying: Common Stock · 3,676 shares Expires 2032-05-13 Read SEC document
May 13, 2022 Filed May 17, 2022 19:28 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	1,503	$0.00	$0.00	Disclosure SEC source: 0000899243-22-018458 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,003 F1 · kind: These restricted stock units will be settled in common stock upon vesting. F2 · shares: These restricted stock units shall vest in full on May 13, 2023. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
April 01, 2022 Filed Apr 4, 2022 17:02 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	Tax withholdingCommon Stock	58,883	$1.12	$65,948.96	Disclosure SEC source: 0001209191-22-022499 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,723 F1 · kind: Represents shares used to cover tax withholding on a Restricted Stock Unit release. F2 · balance_after: Includes 129,117 shares of common stock released from the Restricted Stock Unit award reported on a Form 4 dated February 14, 2019. Read SEC document
March 02, 2022 Filed Mar 4, 2022 17:09 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $20.04	$0.00	Disclosure SEC source: 0000899243-22-009424 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested at a rate of 25% on 3/19/13 and monthly thereafter until all the options were fully vested on 3/19/16. Read SEC document
March 02, 2022 Filed Mar 4, 2022 17:09 UTC	Seagen Inc. SGEN · Entity 13956	Exercise / conversionCommon Stock	25,000	$20.04	$501,000.00	Disclosure SEC source: 0000899243-22-009424 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document
February 15, 2022 Filed Feb 17, 2022 16:05 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantRestricted Stock Units · Derivative	400,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-010702 · doc4.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025. F4 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025. Read SEC document
February 15, 2022 Filed Feb 17, 2022 16:05 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantRestricted Stock Units · Derivative	240,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-010702 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023. F3 · derivative.expiration_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023. Read SEC document
February 15, 2022 Filed Feb 17, 2022 16:05 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantStock Option (right to buy) · Derivative	375,000	$0.00 Strike: $1.59	$0.00	Disclosure SEC source: 0001209191-22-010702 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. Read SEC document
May 14, 2021 Filed May 18, 2021 19:35 UTC	Seagen Inc. SGEN · Entity 13956	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,462	$0.00 Strike: $147.50	$0.00	Disclosure SEC source: 0001203311-21-000036 · edgardoc.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,462 Underlying: Common Stock · 3,462 shares Expires 2031-05-14 Read SEC document
May 14, 2021 Filed May 18, 2021 19:35 UTC	Seagen Inc. SGEN · Entity 13956	GrantCommon Stock	1,402	$0.00	$0.00	Disclosure SEC source: 0001203311-21-000036 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 14, 2022. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.